Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.68 |
| ▸ | LONP1 | P36776 | 12/20 | 0.68 |
| ▸ | PSMB8 | P28062 | 11/20 | 0.68 |
| ▸ | PSMB9 | P28065 | 11/20 | 0.68 |
| ▸ | PSMB6 | P28072 | 11/20 | 0.68 |
| ▸ | PSMB10 | P40306 | 11/20 | 0.68 |
| ▸ | PSMB11 | A5LHX3 | 10/20 | 0.68 |
| ▸ | PSMA7 | O14818 | 10/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 10/20 | 0.68 |
| ▸ | PSMA1 | P25786 | 10/20 | 0.68 |
| ▸ | PSMA2 | P25787 | 10/20 | 0.68 |
| ▸ | PSMA3 | P25788 | 10/20 | 0.68 |
| ▸ | PSMA4 | P25789 | 10/20 | 0.68 |
| ▸ | PSMA5 | P28066 | 10/20 | 0.68 |
| ▸ | PSMB4 | P28070 | 10/20 | 0.68 |
| ▸ | PSMB3 | P49720 | 10/20 | 0.68 |
| ▸ | PSMB2 | P49721 | 10/20 | 0.68 |
| ▸ | PSMA6 | P60900 | 10/20 | 0.68 |
| ▸ | PSMA8 | Q8TAA3 | 10/20 | 0.68 |
| ▸ | PSMB7 | Q99436 | 10/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL28490857 | 1.00 | PSMB5 (0.68) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL19712512 | 0.97 | PSMB5 (0.66) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL1406108 | 0.97 | PSMB5 (0.66) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL1041561 | 0.94 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL21955431 | 0.94 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Leucine SCHEMBL2336540 | 0.94 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| D-Leucine SCHEMBL2338392 | 0.94 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL234139 | 0.90 | PSMB5 (0.71) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL20496418 | 0.86 | PSMB5 (0.58) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL2127762 | 0.86 | PSMB5 (0.73) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443128-B1 | New synthetic route for the preparation of alpha-amino boronic esters | LEK PHARMACEUTICALS (SI) | 2017-12-20 | — | — | EP | claimed |
| EP-2251344-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-30 | — | — | EP | claimed |
| EP-1492545-B1 | AGENTS FOR TREATING I FLAVIVIRIDAE /I INFECTIONS | VIROLOGIK GMBH (DE) | 2010-09-15 | — | — | EP | claimed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | claimed |
| US-20070265194-A1 | Agents for the treatment of viral infections | SCHUBERT ULRICH | 2007-11-15 | — | — | US | claimed |
| US-20060199772-A1 | Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy | CHARITE'-UNIVERSITAETSMEDIZIN BERLIN (DE) | 2006-09-07 | — | — | US | claimed |
| US-20040106539-A1 | Agents for the treatment of viral infections | VIROMICS GMBH (DE) | 2004-06-03 | — | — | US | claimed |
| EP-0788360-B1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2003-05-28 | — | — | EP | claimed |
| US-20100135966-A1 | AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS | SCHUBERT ULRICH | 2010-06-03 | — | — | US | disclosed |
| US-20070265194-A1 | Agents for the treatment of viral infections | SCHUBERT ULRICH | 2007-11-15 | — | — | US | disclosed |
| US-20060199772-A1 | Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy | CHARITE'-UNIVERSITAETSMEDIZIN BERLIN (DE) | 2006-09-07 | — | — | US | disclosed |
| US-20050203029-A1 | Agents for treating <I>flaviviridae</I>infections | SCHUBERT ULRICH (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1524977-A2 | USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE PROTEASOME INHIBITOR THERAPY | Charité - Universitätsmedizin Berlin (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20040106539-A1 | Agents for the treatment of viral infections | VIROMICS GMBH (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004012732-A2 | USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE PROTEASOME INHIBITOR THERAPY | Charité-Universitätsmedizin Berlin (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265194-A1 | Agents for the treatment of viral infections | UBQLN1, CUL4A, UBQLN2 | PSMB5 25/4885LONP1 120/4885PSMB8 26/4885 |
| US-20040106539-A1 | Agents for the treatment of viral infections | PSMB1, PSMB6, PSMB5 | PSMB5 3/4885LONP1 350/4885PSMB8 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.